Dihexa
Dihexa Acetate • Also called N-hexanoic-Tyr-Ile-(6) aminohexanoic amide
Dihexa is marketed in nootropic and neuro-regeneration circles, but the FDA currently places it in the restricted compounding group.
Current status
Restricted
Cognitive-related interest, with current federal compounding constraints still in play.
FDA category
Category 2
Can pharmacies compound this?
No
Reclassification expected?
Unclear
There is far less visible formal momentum around Dihexa than around the higher-profile peptides now in PCAC review.
Primary Use
Cognitive-related interest
Also searched as
N-hexanoic-Tyr-Ile-(6) aminohexanoic amide
Regulatory Timeline
Feb 27, 2026
Political pressure and market expectations increased around a future peptide reclassification review.
Sep 27, 2024
Current status signal recorded: Listed by FDA in Category 2 for significant safety concerns..
Mar 15, 2023
FDA peptide compounding scrutiny intensified across 503A and 503B channels.
Get notified...
Get notified when Dihexa status changes
State-specific notes
Florida
Online interest remains higher than compliant pharmacy access.